Stelex

Stelexis Therapeutics is a biotechnology company focused on the discovery and development of novel cancer therapeutics that target pre-cancerous stem cells (PCSCs). Founded in 2017 and headquartered in New York City, the company utilizes a proprietary platform to identify and selectively target the earliest stages of cancer development, particularly in hematologic malignancies like Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). By focusing on the "seeds" of cancer, Stelexis aims to develop transformative treatments that prevent disease progression and relapse. The company is backed by Deerfield Management and was co-founded by a team of world-renowned scientists, including Moderna co-founder Derrick Rossi.